Day: December 13, 2020

ABO-GROUP acquires French engineering firm GEO+ Environnement.

Written by Customer Service on . Posted in Public Companies.

Ghent, 13 December 2020, 5 p.m.Press release / Regulated informationABO-GROUP acquires French engineering firm GEO+ Environnement.ABO-GROUP will acquire all the shares of the French GEO+ Environnement company at the beginning of January 2021. GEO+ Environnement has its head offices in Gardouch, near Toulouse, in the French department of Haute-Garonne, and has four offices in Central, North, East and South-West France.Thanks to around 25 hydrogeologists, ecologists and geologists, the added expertise and knowledge in the mining, quarrying and dyke sectors can thereby also be offered to the other ABO-GROUP home countries.GEO+ Environnement is an independent consultancy specialised in environmental advice in the mineral industry (mines and quarries), with expertise in environment, geology and hydraulic engineering. It is the French reference...

Continue reading

ABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over

Written by Customer Service on . Posted in Public Companies.

Gent, 13 december 2020, 17 uPersbericht / Gereglementeerde informatieABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over.ABO-GROUP verwerft begin januari 2021 alle aandelen van het Franse GEO+ Environnement. GEO+ Environnement heeft haar hoofdzetel in Gardouch, nabij Toulouse, in het Franse departement Haute-Garonne, met vier kantoren verspreid in het center, het Noorden, Oosten en Zuidwesten van Frankrijk.De toegevoegde expertise en kennis in de sector van mijnbouw, steengroeven en dijken kan dankzij een 25-tal hydrogeologen, ecologen en geologen, hierbij ook in de andere thuislanden van ABO-GROUP aangeboden worden.GEO+ Environnement is een onafhankelijk adviesbureau gespecialiseerd in milieuadvies in de minerale industrie (mijnen en steengroeven), met een expertise in milieu, geologie en waterbouw. Het is hét Frans referentiebureau...

Continue reading

ABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement

Written by Customer Service on . Posted in Public Companies.

Gand, le 13 décembre 2020, 17 heuresCommuniqué de presse / Information réglementéeABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement.ABO-GROUP acquerra la totalité des actions de la société française GEO+ Environnement au début du mois de janvier 2021. GEO+ Environnement a son siège social à Gardouch, près de Toulouse, dans le département français de la Haute-Garonne, avec quatre bureaux dans le centre, le nord, l’est et le sud-ouest de la France.À la clef : une expertise et des connaissances supplémentaires dans le secteur des mines, des carrières et des digues qui pourront désormais être également proposées dans les autres pays d’activité d’ABO-GROUP, grâce à quelque 25 hydrogéologues, écologistes et géologues.GEO+ Environnement est un bureau d’études indépendant spécialisé dans le conseil environnemental...

Continue reading

TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors

Written by Customer Service on . Posted in Public Companies.

– TC-210 induced tumor regression in all of the first eight patients– Ovarian cancer patient achieved confirmed RECIST partial response (PR)– Overall response rate (ORR) 50% in patients infused with TC-210 and lymphodepletion      – Continued manageable toxicity profile      – Phase 1 trial amended to accelerate treatment– TCR2 to host conference call Monday, December 14 starting at 8:00am E.T. live webcast availableCAMBRIDGE, Mass., Dec. 13, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing...

Continue reading

Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020

Written by Customer Service on . Posted in Public Companies.

VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading doseVASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care groupLarger follow-on clinical studies have commenced of VASCEPA as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021Amarin to Webcast Discussion of Presented Data on Monday, December 14, 2020 at 8:00 a.m., Eastern Standard TimeDUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 12, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.